Akute Transaminasenerhöhung/Hepatitis bei SJIA unter Therapie mit Anakinra

• Literatur

• 1 Mellins ED. et al. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011; 7: 416-426.
• 2 Sikora KA, Grom AA. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr Opin Pediatr 2011; 23 (06) 640-646.
• 3 Pascual V. et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201 (09) 1579-1586.
• 4 Frosch M, Roth J. New insights in systemic juvenile idiopathic arthritis – from pathophysiology to treatment. Rheumatology 2008; 47 (02) 121-125.
• 5 Quartier P. et al. A multicentre, randomised, double-blind, placebo-controlled trial with interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANA-JIS trial). Ann Rheum Dis 2011; 70: 747-754.
• 6 Swart SF. et al. The efficacy and safety of interleukin-1 receptor antogonist anakinra in the treatment of systemic juvenile idiopathic arthritis. Exp Opin Biol Ther 2010; 10 (12) 11743-11752.
• 7 Gattorno M. et al. The pattern of response to Anti-Interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile arthritis. Arthr Rheum 2008; 58: 1505-1515.
• 8 Lequerré T. et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302-308.
• 9 Nigrovic PA. et al. Anakinra as first-line diseasemodifying therapy in systemic juvenile idiopathic arthritis. Arthr Rheum 2011; 63 (02) 545-555.
• 10 Beukelman T. et al. 2011 American college of rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 64 (04) 465-482.
• 11 Davi S. et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2011; 38 (04) 764-768.
• 12 Hiejima E. et al. Acute liver failure in young children with systemic-onset juvenile idiopathic arthritis without macrophage activation syndrome: report of two cases. J Paediatr Child Health. 2011 Nov 3. [Epub ahead of print]
• 13 Andrès E. et al. Retrospective monocentric study of 17 patients with adult Still’s disease, with specific focus on liver abnormalities. Hepatogastroenterology 2003; 50 (49) 192-195.
• 14 Zhu G. et al. Liver abnormalities in adult onset Still´s disease. A restrospective study of 77 chinese patients. J Clin Rheumatol 2009; 15 (06) 284-288.
• 15 Emery P. et al. Il-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008; 67: 1116-1123.
• 16 Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010; 3: 81-89.
• 17 Canna S. et al. Acute hepatitis in three patients with systemic idiopathic arthritis taking interleukin-I receptor antagonist. Pediatr Rheumatol Online J. 2009 7. (21)
• 18 Stokes CA. et al. Role of interleukin-1 and MyD88-dependent signaling in rhinovirus infection. J Virol 2011; 85 (15) 7912-7921.